• Strategic: Create options for the corporation to expand into new therapeutic approaches and businesses
  

• Add value: Help innovators develop their concept from idea to Proof of Concept
  

• Secure financial return to support continuity --> Evergreen Fund Model

External environment:

• 2009: Venture investment declined to a 12-year low
• Novel concepts would not be progressed due to lack of financing

Inside view: stepwise approach:

• Boehringer Ingelheim has built a strong pipeline based on inhouse R&D
• Boehringer Ingelheim's pipeline has been complemented via licensing deals and research collaborations
• BIVF will create options to expand into new therapeutic approaches and businesses

• Address "undrugable" targets, e.g.  targets that are poorly amenable to either current NCEs or NBEs
• Next generation vaccines, e.g. T-Cell vaccines
• Next generation NBEs, e.g. cancer immunotherapeutics
• Regenerative medicine
• New platforms for Targets and Biomarkers identification

• Total fund volume: €100 Mio
• Initial investment at an early stage of company's life
• Follow-on investments in pace with the company's progress
• Staged investments of up to €10 mio over company's lifetime

• Strategic orientation: Long-term view
• Family owned: Continuity, Cultural Identity
• No option required: Openess to join VC syndicates        
• Successful track record in R&D: Able and willing to provide scientific, managerial and commercial support
• Help positioning portfolio companies for an exit